December 6, 2019 09:20 AM ESTUpdated 09:31 AM

Black Diamond raises another $85M to bring new oncogene approach into clinic

Jason Mast

Editor

Nearly a year after raising $85 million from investors, Black Diamond Therapeutics has raised another $85 million to help push its allosteric therapies into the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Black Diamond raises another $85M to bring new oncogene approach into clinic

Jason Mast

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Black Di­a­mond rais­es an­oth­er $85M to bring new onco­gene ap­proach in­to clin­ic

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Black Diamond raises another $85M to bring new oncogene approach into clinic